908 Devices (NASDAQ:MASS – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03, Zacks reports. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. 908 Devices updated its FY 2025 guidance to EPS.
908 Devices Price Performance
NASDAQ MASS opened at $3.31 on Tuesday. 908 Devices has a 1 year low of $1.81 and a 1 year high of $7.56. The company has a market capitalization of $115.23 million, a PE ratio of -1.90 and a beta of 0.99. The company has a fifty day moving average of $2.42 and a 200 day moving average of $2.94.
Analysts Set New Price Targets
Several equities analysts have issued reports on MASS shares. Stifel Nicolaus cut their price target on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Leerink Partnrs downgraded 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 price objective (down from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Stephens restated an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a research note on Wednesday, January 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of 908 Devices in a research report on Wednesday, February 19th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, 908 Devices presently has an average rating of “Moderate Buy” and an average target price of $5.33.
About 908 Devices
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
See Also
- Five stocks we like better than 908 Devices
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Intuitive Machines: March 6 Is a Pivotal Day for Lunar Economy
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Rocket Lab’s Plunge: Buy the Dip or Watch from the Sidelines?
- Investing In Automotive Stocks
- Mediterranean Growth Monster: CAVA Keeps Surging—Buy the Dip?
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.